Research programme: small molecules - Crinetics Pharmaceuticals

Drug Profile

Research programme: small molecules - Crinetics Pharmaceuticals

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crinetics Pharmaceuticals
  • Class Analgesics; Antineoplastics; Small molecules
  • Mechanism of Action Somatostatin receptor 2 agonists; Somatostatin receptor 5 agonists; Somatostatin receptor subtype 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cushing syndrome; Hyperinsulinaemia; Neuroendocrine tumours; Pain

Most Recent Events

  • 12 Sep 2017 Chronic pain candidate is available for licensing as of 12 Sep 2017. http://www.crinetics.com/therapeutics/
  • 12 Sep 2017 Early research in Pain in USA (PO) before September 2017 (Crinetics Pharmaceuticals pipeline, September 2017)
  • 06 Sep 2017 Crinetics Pharmaceuticals recieves two SBIR grants from NIDDK and NIH for Hyperinsulinaemia and Cushing's Disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top